Vaccine potentially could be used in the majority of breast cancer patients
Dec. 3, 2014
| By Diane Mapes / Fred Hutch News Service
They may be baby steps, but researchers at Washington University School of Medicine in St. Louis took a few more of them this week with the publication of a study looking at a potential new breast cancer vaccine. Fred Hutch researchers weigh in and discuss their own breast cancer vaccine-related work.
Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies
April 11, 2011
Research institutions at 27 sites across North America have been selected as part of the Cancer Immunotherapy Trials Network, based at the Fred Hutchinson Cancer Research Center. A new initiative in immunotherapy, CITN unites top academic immunologists to conduct multicenter research on therapies that boost patients’ own immune systems to fight cancer.
Center to lead national, multi-institutional clinical trials effort
Oct. 11, 2010
In an effort to accelerate clinical trials of promising cancer immunotherapies, the National Cancer Institute has awarded a five-year, $17 million grant to the Fred Hutchinson Cancer Research Center Clinical Research Division’s Dr. Mac Cheever to establish a new Cancer Immunotherapy Trials Network.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.